Format

Send to

Choose Destination
Cancer Cell. 2018 Apr 9;33(4):547-562. doi: 10.1016/j.ccell.2018.03.012.

T Cell Dysfunction in Cancer.

Author information

1
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: d.thommen@nki.nl.
2
Division of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Abstract

Therapeutic reinvigoration of tumor-specific T cells has greatly improved clinical outcome in cancer. Nevertheless, many patients still do not achieve durable benefit. Recent evidence from studies in murine and human cancer suggest that intratumoral T cells display a broad spectrum of (dys-)functional states, shaped by the multifaceted suppressive signals that occur within the tumor microenvironment. Here we discuss the current understanding of T cell dysfunction in cancer, the value of novel technologies to dissect such dysfunction at the single cell level, and how our emerging understanding of T cell dysfunction may be utilized to develop personalized strategies to restore antitumor immunity.

KEYWORDS:

PD-1; T cell exhaustion; cancer; cancer immunotherapy; single cell technologies; tumor microenvironment

PMID:
29634943
DOI:
10.1016/j.ccell.2018.03.012
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center